XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.4
Certain Balance Sheet Components
 9 Months Ended
Dec. 31, 2021
Other Liabilities Disclosure [Abstract]  
Certain Balance Sheet Components Certain Balance Sheet Components
Cash, Cash Equivalents and Restricted Cash
The following represents a reconciliation of cash and cash equivalents in the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the unaudited condensed consolidated statements of cash flows (in thousands):
December 31,
20212020
Cash and cash equivalents$457,742 $713,523 
Restricted cash10,100 2,987 
Total cash, cash equivalents and restricted cash$467,842 $716,510 
Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash (maturity of three months or less at the time of purchase). Restricted cash consists of funds held or designated to satisfy the requirements of certain agreements that are restricted in their use and are included in other assets on the unaudited condensed consolidated balance sheets. As of December 31, 2021, restricted cash includes approximately $7.1 million that is held in an escrow fund for use by Sunovion Pharmaceuticals Inc. (“Sunovion”), a subsidiary of Sumitomo Dainippon Pharma, to manage payments for rebates, chargebacks, and similar fees pursuant to the Market Access Services Agreement (see Note 5(C)).
Inventories
As of December 31, 2021 and March 31, 2021, inventories consisted of the following (in thousands):
December 31, 2021March 31, 2021
Raw materials$823 $1,390 
Work in process1,405 773 
Finished goods4,509 448 
Total inventories$6,737 $2,611 
Accrued Expenses and Other Current Liabilities
As of December 31, 2021 and March 31, 2021, accrued expenses and other current liabilities consisted of the following (in thousands):
December 31, 2021March 31, 2021
Accrued compensation-related expenses$22,201 $20,571 
Accrued sales discounts, rebates, and allowances15,549 1,315 
Accrued R&D expenses6,463 8,544 
Accrued commercial expenses8,309 7,770 
Accrued other expenses5,259 5,315 
Accrued professional fees642 935 
Deferred product revenue— 162 
Total accrued expenses and other current liabilities$58,423 $44,612